Vivus at outperform by RBC

RBC Capital Markets analyst Ken Trbovich put Vivus at outperform, speculative risk after the European Committee for Medicinal Products for Human Use recommended approval of Proctor & Gamble's Intrinsa, which Trbovich said is good news for Vivus' Testosterone MDTS. Shares of the Mountain View, Calif.-based pharmaceutical company were down $0.21, or 4.46%, at $4.50 on volume of 238,544 shares versus the three-month running average of 458,115shares. (Nasdaq: VVUS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.